Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

NICE technology appraisals [TA118] Published date:

This guidance has been partially updated by TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)

Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for people with metastatic colorectal cancer who have not been treated before.

Cetuximab in combination with irinotecan is not recommended for people with metastatic colorectal cancer who have had previous treatment for the cancer that also included irinotecan.

Consultants should not stop prescribing bevacizumab or cetuximab for people who were already taking it when the guidance was issued. These patients should be able to carry on taking bevacizumab or cetuximab until they and their consultants decide that it is the right time to stop treatment.

Get involved